Kainos Medicine, Inc. (KOSDAQ: 284620)
South Korea
· Delayed Price · Currency is KRW
3,225.00
-40.00 (-1.23%)
Dec 20, 2024, 12:32 PM KST
Kainos Medicine Statistics
Total Valuation
Kainos Medicine has a market cap or net worth of KRW 94.55 billion.
Market Cap | 94.55B |
Enterprise Value | n/a |
Important Dates
Earnings Date | n/a |
Ex-Dividend Date | n/a |
Share Statistics
Kainos Medicine has 28.18 million shares outstanding.
Current Share Class | n/a |
Shares Outstanding | 28.18M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 10.53% |
Owned by Institutions (%) | n/a |
Float | 25.21M |
Valuation Ratios
The trailing PE ratio is 2,368.42.
PE Ratio | 2,368.42 |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | 0.91 |
P/TBV Ratio | 4.77 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
Current Ratio | n/a |
Quick Ratio | n/a |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 0.20% and return on invested capital (ROIC) is 0.19%.
Return on Equity (ROE) | 0.20% |
Return on Assets (ROA) | n/a |
Return on Capital (ROIC) | 0.19% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.09% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -28.09% |
50-Day Moving Average | 3,903.30 |
200-Day Moving Average | 4,015.38 |
Relative Strength Index (RSI) | 53.63 |
Average Volume (20 Days) | 526,359 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | 60.74M |
Pretax Income | 60.74M |
Net Income | 39.92M |
EBITDA | n/a |
EBIT | 60.74M |
Earnings Per Share (EPS) | 6.18 |
Balance Sheet
Cash & Cash Equivalents | n/a |
Total Debt | n/a |
Net Cash | n/a |
Net Cash Per Share | n/a |
Equity (Book Value) | 19.83B |
Book Value Per Share | 3,672.38 |
Working Capital | n/a |
Cash Flow
Operating Cash Flow | 169.79M |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Kainos Medicine does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -1,474.97% |
Shareholder Yield | -1,474.97% |
Earnings Yield | 0.18% |
FCF Yield | n/a |
Stock Splits
The last stock split was on June 24, 2022. It was a reverse split with a ratio of 0.2.
Last Split Date | Jun 24, 2022 |
Split Type | Reverse |
Split Ratio | 0.2 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |